1 Table of Contents
1.1 List of Tables
List of Figures

2 Executive Summary
2.1 Cognitive Impairment Associated With Schizophrenia (CIAS)- Disease Overview
2.2 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pipeline Snapshot
2.3 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pipeline Drugs by Phase
2.4 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pipeline Drugs by Company
2.5 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 Anvyl LLC Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.2 Astellas Pharma Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.3 AstraZeneca Plc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.4 Autifony Therapeutics Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.5 Biogen Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.6 Boehringer Ingelheim GmbH Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.7 Bristol-Myers Squibb Co Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.8 Cadent Therapeutics Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.9 Coronis NeuroSciences Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.10 Eli Lilly and Co Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.11 F. Hoffmann-La Roche Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.12 Iproteos SL Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.13 Pfizer Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.14 SK Biopharmaceuticals Co Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.15 Sosei Heptares Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.16 Spherium Biomed SL Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.17 Suven Neurosciences Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.18 Takeda Pharmaceutical Co Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019
3.19 Vanda Pharmaceuticals Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 1 Drug Details
4.2 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 1 Drug Overview
4.3 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 2 Drug Details
5.2 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 2 Drug Overview
5.3 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 3 Drug Details
6.2 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 3 Drug Overview
6.3 Cognitive Impairment Associated With Schizophrenia (CIAS)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pre-clinical Phase Drug Details
7.2 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pre-clinical Phase Drug Overview
7.3 Cognitive Impairment Associated With Schizophrenia (CIAS)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About VPAResearch
9.2 Sources and Research Methodology

Companies mentioned
Anvyl LLC, Astellas Pharma Inc, AstraZeneca Plc, Autifony Therapeutics Ltd, Biogen Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Cadent Therapeutics, Coronis NeuroSciences Ltd, Eli Lilly and Co, F. Hoffmann-La Roche Ltd, Iproteos SL, Pfizer Inc, SK Biopharmaceuticals Co Ltd, Sosei Heptares, Spherium Biomed SL, Suven Neurosciences Inc, Takeda Pharmaceutical Co Ltd, Vanda Pharmaceuticals Inc